George van Andel

4.8k total citations · 4 hit papers
47 papers, 3.3k citations indexed

About

George van Andel is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, George van Andel has authored 47 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 19 papers in Surgery and 13 papers in Oncology. Recurrent topics in George van Andel's work include Prostate Cancer Treatment and Research (21 papers), Prostate Cancer Diagnosis and Treatment (20 papers) and Bladder and Urothelial Cancer Treatments (14 papers). George van Andel is often cited by papers focused on Prostate Cancer Treatment and Research (21 papers), Prostate Cancer Diagnosis and Treatment (20 papers) and Bladder and Urothelial Cancer Treatments (14 papers). George van Andel collaborates with scholars based in Netherlands, Belgium and United Kingdom. George van Andel's co-authors include Paolo Gontero, Richard Sylvester, Jorg R. Oddens, Maurizio Brausi, Levent Türkeri, Sandra Collette, Maarten C.C.M. Hulshof, Andrew Bottomley, C. van de Beek and Willem Oosterlinck and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

George van Andel

45 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of a Comprehensive Surgical Safety System on Patient Outcomes

2010 651 citations George van Andel et al. profile →
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin

2015 444 citations Richard Sylvester, Paolo Gontero et al. European Urology profile →
Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

2012 340 citations Jorg R. Oddens, Maurizio Brausi et al. European Urology profile →
Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial

2018 336 citations Liselotte M.S. Boevé, Maarten C.C.M. Hulshof et al. European Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
George van Andel Netherlands	22	1.4k	1.1k	737	434	427	47	3.3k
Christopher J.D. Wallis Canada	32	880 0.6×	1.8k 1.6×	995 1.4×	128 0.3×	207 0.5×	250	4.2k
David C. Miller United States	29	731 0.5×	979 0.9×	536 0.7×	82 0.2×	162 0.4×	125	2.8k
Jesse D. Sammon United States	45	2.2k 1.6×	3.7k 3.3×	1.3k 1.7×	118 0.3×	834 2.0×	218	6.2k
Kamal Nagpal United Kingdom	23	924 0.7×	498 0.4×	261 0.4×	455 1.0×	49 0.1×	46	2.2k
Raj Satkunasivam United States	22	775 0.6×	762 0.7×	415 0.6×	116 0.3×	309 0.7×	113	2.4k
Shyam Sukumar United States	34	1.1k 0.8×	1.6k 1.4×	345 0.5×	77 0.2×	471 1.1×	94	2.7k
Omar Faiz United Kingdom	49	4.3k 3.1×	1.6k 1.4×	2.8k 3.8×	135 0.3×	53 0.1×	245	7.2k
Simon P. Kim United States	43	2.5k 1.8×	3.3k 2.9×	1.2k 1.6×	73 0.2×	859 2.0×	198	6.0k
Peter W. Dillon United States	29	2.1k 1.5×	1.3k 1.1×	216 0.3×	160 0.4×	62 0.1×	85	3.3k
Steven C. Stain United States	39	2.4k 1.7×	1.3k 1.2×	1.0k 1.4×	138 0.3×	28 0.1×	136	4.2k

Countries citing papers authored by George van Andel

Since Specialization

Citations

This map shows the geographic impact of George van Andel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George van Andel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George van Andel more than expected).

Fields of papers citing papers by George van Andel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George van Andel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George van Andel. The network helps show where George van Andel may publish in the future.

Co-authorship network of co-authors of George van Andel

This figure shows the co-authorship network connecting the top 25 collaborators of George van Andel. A scholar is included among the top collaborators of George van Andel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George van Andel. George van Andel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Boevé, Liselotte M.S., Maarten C.C.M. Hulshof, Paul C.M.S. Verhagen, et al.. (2024). Prostate Cancer–related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial. European Urology. 87(3). 357–363. 2 indexed citations

Boevé, Liselotte M.S., et al.. (2023). Cancer detection and complications of transperineal prostate biopsy with antibiotics when indicated. British Journal of Urology. 132(4). 397–403. 5 indexed citations

Boevé, Liselotte M.S., Maarten C.C.M. Hulshof, Paul C.M.S. Verhagen, et al.. (2020). Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial. European Urology. 79(2). 188–197. 23 indexed citations

Pos, Floris J., Maarten C.C.M. Hulshof, Robin W.M. Vernooij, et al.. (2019). Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based Study. European Urology Focus. 7(2). 332–339. 8 indexed citations

Andel, George van, et al.. (2019). The Feasibility and Utility of Cystoscopy-Guided Hydrogel Marker Placement in Patients With Muscle-Invasive Bladder Cancer. Practical Radiation Oncology. 10(3). 195–201. 3 indexed citations

Oort, Inge M. van, George van Andel, Floris J. Pos, et al.. (2018). Immediate treatment vs. active-surveillance in very-low-risk prostate cancer: the role of patient-, tumour-, and hospital-related factors. Prostate Cancer and Prostatic Diseases. 22(2). 337–343. 3 indexed citations

Brausi, Maurizio, Jorg R. Oddens, Richard Sylvester, et al.. (2013). Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG. European Urology. 65(1). 69–76. 244 indexed citations

Andel, George van, Andrew Bottomley, Sophie D. Fosså, et al.. (2008). An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer. European Journal of Cancer. 44(16). 2418–2424. 368 indexed citations

Blaauwgeers, Hans, et al.. (2006). Pseudomelanosis of the Bladder. Acta Cytologica. 50(4). 473–475. 10 indexed citations

10.

Fischer, Maarten J., et al.. (2006). Features of members of a prostate cancer patients’ association. The Journal of Men s Health and Gender. 3(4). 379–389. 2 indexed citations

11.

Fischer, Maarten J., et al.. (2006). Health-Related Quality of Life in Dutch Men with Prostate Cancer. Journal of Psychosocial Oncology. 24(2). 49–64. 12 indexed citations

12.

Andel, George van, Christien Caris, P. Carpentier, et al.. (2003). A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life. World Journal of Urology. 21(3). 177–182. 11 indexed citations

13.

Andel, George van, Adriaan Visser, Maarten C.C.M. Hulshof, Simon Horenblas, & K. H. Kurth. (2003). Health‐related quality of life and psychosocial factors in patients with prostate cancer scheduled for radical prostatectomy or external radiation therapy. British Journal of Urology. 92(3). 217–222. 16 indexed citations

14.

Andel, George van & K. H. Kurth. (2003). The Impact of Androgen Deprivation Therapy on Health Related Quality of Life in Asymptomatic Men with Lymph Node Positive Prostate Cancer. European Urology. 44(2). 209–214. 50 indexed citations

15.

Visser, Adriaan, et al.. (2003). Changes in health-related quality of life of men with prostate cancer 3 months after diagnosis: the role of psychosocial factors and comparisment with benign prostate hyperplasia patients. Patient Education and Counseling. 49(3). 225–232. 25 indexed citations

16.

Andel, George van, et al.. (2000). Quality of Life Assessment in Patients with Hormone–Resistant Prostate Cancer Treated with Epirubicin or with Epirubicin plus Medroxy Progesterone Acetate – Is It Feasible?. European Urology. 38(3). 259–264. 13 indexed citations

17.

Haarst, Ernst P. van, et al.. (1999). Value of diagnostic ultrasound in patients with chronic scrotal pain and normal findings on clinical examination. Urology. 54(6). 1068–1072. 21 indexed citations

18.

Andel, George van, K. H. Kurth, & J.C.J.M. de Haes. (1997). Quality of life in patients with prostatic carcinoma: A review and results of a study in N+ disease Prostate-specific antigen as predictor of quality of life. Urological Research. 25(S2). S79–S88. 15 indexed citations

19.

Craen, Anton JM de, et al.. (1996). Does Prostate-Specific AntigenDensity Alter Decision Making onBiopsy?. European Urology. 29(1). 10–14. 2 indexed citations

20.

Andel, George van, et al.. (1995). Incidental carcinoma of the prostate. Seminars in Surgical Oncology. 11(1). 36–45. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact